Brian M. Strem - 26 Jul 2021 Form 4 Insider Report for EYEGATE PHARMACEUTICALS INC (KPRX)

Role
President and CEO, Director
Signature
/s/ Sarah Romano, Attorney-in-Fact*
Issuer symbol
KPRX
Transactions as of
26 Jul 2021
Net transactions value
$0
Form type
4
Filing time
02 Aug 2021, 17:30:52 UTC
Next filing
22 Nov 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KPRX Stock Option (right to buy) Award $0 +100,000 $0.000000 100,000 26 Jul 2021 Common Stock 100,000 $3.12 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on July 26, 2022, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.